Exciting research in the field of gastrointestinal cancer
1.Pd-1 combined chemotherapy to treat gastric cancer, tumor control rate 92%
In the field of cancer of the stomach, ASCO conference announced a set of clinical data: let a person very shocked PD - 1 antibodies for first diagnosis of gastric cancer patients with combination chemotherapy, effective rate was 60%, the disease control rates at least 92%, the median survival period of 20.8 months!
This research is encouraging for experts and scholars who have been working in the field of gastric cancer for a long time.
The study involved a total of 25 patients with gastric cancer in the early stages of the disease, using the pd-1 antibody Keytruda, 200 mg, and 3 Monday.
5 - FU, 800 mg/m2;
Cisplatin, 80mg/m2.
The results showed that the tumors of 15 patients in the 25 patients were significantly reduced and 60 percent effective.
The tumor was stable and the disease control rate was 92%.
Remarkably, the tumors of the 24 patients were reduced to varying degrees, and the median survival time for all patients was 20.8 months.
For first diagnosis of gastric cancer patients (excluding its ehrs positive - 2), a line of chemotherapy regimens of median survival generally not more than 15 months, and the research to the median surial in patients with increased to 20.8 months, in the treatment of the cancer of the stomach is very not easy, the only fly in the ointment was the study sample cases, few expect the combined treatment can be confirmed in larger clinical trials.
2.Vitamin D supplements to delay the progress of colorectal cancer?
The effects of vitamins on tumors have been closely watched by researchers, and the ASCO conference also published a study of vitamin D supplementation for colorectal cancer - the SUNSHINE phase 2 clinical trial.
The study was led by Dr. KimmieNg of the Dana Farber cancer institute in Boston, USA.
All into the group of patients undergoing mFOLFOX6 + beacizumab bead on the basis of resistance to standard treatment alone, 1:1 randomly into the high dose group and low dose group, vitamin D until disease progression or cannot tolerate or withdraw the informed consent and out of the group.
Patients in high-dose groups were first given a dose of vitamin D of 8000 IU/day of VD3 2 weeks, followed by a dose of 4, 000 IU/day.
Patients in low-dose groups received standard doses of VD3 (400 IU/day).
The results showed that the higher dose group (n = 69), the lower dose group (n = 70) was 13.1 VS11.2 (month), and the disease control rate of the high-dose group and the low-dose group was 96% vs 84% (P = 0.05).
The most common 3-4 levels of toxicity were both FOLFOX and bevacizumab, with no significant correlation with vitamin D.
The incidence of diarrhea was significantly lower in grade 3 or level 4 (12% VS1 %; P = 0.02).
The secondary key OS of this study is not yet reached, and further data is expected.
The study also requires large phase III clinical studies to verify this.
prev:Exciting research in breast cancer(2017-07-04)
next:About immune precipitation, here is a detailed description!(2017-07-05)